RE:RE:Question for the Pharma SavvyN0taP00p wrote: For many (not all) companies at this stage of development and with so much promise, one would think a $300M to $500 M market cap is very reasonable. At least a dollar+ per share. The IP is there, the initial results seem to beat or equal the best out there, safety looks good, and all with just one or two treatments. So what gives? I think it's a combination of the exchange they're on, execution history, unknown names on BOD and exec team wrt go-to-market and scaling experience, and PDT still being on the fringes of oncology for the most part. The last two to three NRs were impressive and reinforced our faith in the science and the drug itself. You just have to hope the FDA will see the potential. Or least another pharma looking for a 10 year diversified pipeline based on Ruvidar. Why not buy a third of the company for 2 bucks and the rest of the acquisition based on meeting BTD and other goals? $200M seems like an informed bet (phase 2, close to BTD) for a hungry pharma.
Agree....this exchange, the current cash position & the legacy of Photofrin can all act like anchors on value. On the bright side, there has been a significant uptick in acquisitions of small/startup biotech companies in the past 6+ months...deals in the <1B to 5B range, of which many of these buyouts were for single indications addressing the high unmet/orphan disease space. Pharma seems to be making a profitable pivot to this space with its bigger margins. Novartis recently acquired Mariana Oncology, a "pre-clinical" radiopharmaceutical company for 1B.
On the surface, this company's tech with its base compound (Ruvidar) has much broader potential than many (if not all) of the biotechs acquired in the past year (in < 5 B range), especially when considering the disparate health conditions (cancer & infectious disease) this tech is now encompassing at various stages of development.
As so many here agree, I certainly would not entertain any deal(s) until we at least have a BTD in hand. Collectively, the future value of our tech is currently immeasurable. As for our Ph 2 NMIBC study, I'd put at least a 1B price tag on it (post BTD)...this includes taking into account its potential "treatment optionality/versatility" for this indication, which I have a hard time discounting. JMO & good luck...